Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab combined with SBRT for recurrent or metastatic adrenocortical carcinoma
ChiCTR2400089134Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University Cancer Center
- Start
- Sep 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in adrenal cancer (ACC), sponsored by Sun Yat-sen University Cancer Center. Primary endpoint: Progression-free survival. Planned start Sep 2024; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
adrenal cancer (ACC)
Beyond the preview
Go deeper on ChiCTR2400089134.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400089134.